Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalent (CTLT) Expands Presence in Japan Via New Facility

by Zacks Equity Research

Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.

Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool

by Zacks Equity Research

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba

by Zacks Equity Research

Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.

Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients

by Zacks Equity Research

Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.

If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

If You Invested $1000 in DexCom 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Stock Market News for Aug 2, 2021

by Zacks Equity Research

Benchmarks closed in the red on Friday, with renewed concerns revolving around the increase in coronavirus cases especially due to delta variant and a disappointing Q2 earnings report from Amazon.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 76.74% and 8.59%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 28th

by Zacks Equity Research

AEVA, BKD, CSGS, DXCM and EIG have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2021.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

Analysts Estimate DexCom (DXCM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod

by Zacks Equity Research

Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.

New Strong Sell Stocks for July 13th

by Zacks Equity Research

ONEM, BABA, DXCM, ORAN, and MTH have been added to the Zacks Rank #5 (Strong Sell) List on July 13, 2021

New Strong Sell Stocks for July 6th

by Zacks Equity Research

DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021

Debanjana Dey headshot

Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus

by Debanjana Dey

CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.

Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia

by Zacks Equity Research

Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.

    DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

    DexCom (DXCM) Surpasses Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    DexCom (DXCM) delivered earnings and revenue surprises of 6.45% and 4.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Trina Mukherjee headshot

    Medical Products' Apr 29 Earnings Roster: TMO, BAX & More

    by Trina Mukherjee

    The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

    Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands

    by Zacks Equity Research

    Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands